Phase I Services
Advarra offers the most comprehensive approach to Phase I research with experience overseeing thousands of Phase I studies in the US and Canada.
CANCELLED – After the Compliance Date: Revised Common Rule FAQs
In this webinar, Michele Russell-Einhorn, JD, Advarra's CCO and IO, and Judith Carrithers, JD, Advarra's Director of Regulatory Affairs, discuss FAQs and common issues in implementing the revised Common Rule.
Making a List, Checking It Twice… The Revised Common Rule Is Coming to Town!
Judith Carrithers, JD, Director of Regulatory Services at Advarra, and Michele Russell-Einhorn, JD, Chief Compliance Officer and Institutional Official at Advarra, discuss a checklist of action items to consider and…
Oversight Challenges with Patient Centered Outcomes Research
Luke Gelinas, PhD, IRB Chair at Advarra, discusses some of the oversight challenges presented by PCOR and shares policy recommendations for managing such challenges.
IRB Services: Canadian Review
Advarra’s Canadian review service combines local, expert oversight with streamlined processes and the most extensive site reach in Canada to aid you in the conduct of efficient, responsible research.
IRB Services: Institutions, AMCs & Research Consortia
Advarra serves as your external support and compliance partner for everything from single investigational sites to multisite research consortia and therapeutic networks.
IRB Services: Study Startup Support
Advarra provides flexible solutions that help accelerate the initial IRB review process and make it more efficient.
IRB Services: Central Oncology Review
Advarra’s Central Oncology Review service provides robust human subject protections review that cancer research institutions expect.
The EU General Data Protection Regulation: Implications for Research
In this webinar, presenters from Ropes & Gray LLP provide an introduction to the GDPR and its potential application to the US-based research community.
Expanded Access and Right to Try: The Impact of Recent Legislative Changes
Presenters from Advarra and Verrill Dana, LLP, provide an overview of the current state of the FDA’s Expanded Access Program and state and federal “Right to Try” legislative efforts.